SCHEMBL4357822

SCHEMBL4357822

Cn1cnc2nc(-c3ccc(F)cc3)n(NCc3ccc(Cl)cc3)c(=O)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 3/20 0.40
ALDH1A1 P00352 4/20 0.39
HTT P42858 2/20 0.39
CYP3A4 P08684 5/20 0.39
USP2 O75604 4/20 0.39
CYP1A2 P05177 4/20 0.39
CASP1 P29466 3/20 0.39
CASP7 P55210 3/20 0.39
HIF1A Q16665 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 2/20 0.38
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353820 0.90 SMN1; SMN2 (0.38) TRPA1ALDH1A1HTTCYP1A2MEN1
SCHEMBL4194181 0.80 ALDH1A1 (0.41) TRPA1ALDH1A1HTTCYP3A4USP2
SCHEMBL4338997 0.80 BRD4 (0.46) TRPA1ALDH1A1HTTCYP3A4USP2
SCHEMBL4202613 0.79 SMN1; SMN2 (0.48) TRPA1ALDH1A1HTTCYP3A4USP2
SCHEMBL4194865 0.78 CYP1A2 (0.49) TRPA1ALDH1A1HTTCYP3A4USP2
SCHEMBL4233295 0.74 SMN1; SMN2 (0.53) ALDH1A1HTTCYP3A4USP2CYP1A2
SCHEMBL4237651 0.74 SMN1; SMN2 (0.67) ALDH1A1HTTCYP3A4CYP1A2MEN1
SCHEMBL4233197 0.74 SMN1; SMN2 (0.48) TRPA1ALDH1A1HTTCYP3A4CYP1A2
SCHEMBL4201045 0.73 RXFP1 (0.52) ALDH1A1HTTCYP3A4USP2CYP1A2
SCHEMBL4194208 0.73 SMN1; SMN2 (0.46) ALDH1A1HTTCYP3A4USP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 TRPA1 670/4885ALDH1A1 2426/4885HTT 1688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.